MiR-30a and miR-379 modulate retinoic acid pathway by targeting DNA methyltransferase 3B in oral cancer.
Alcohol Oxidoreductases
/ genetics
Aldehyde Dehydrogenase 1 Family
/ genetics
Arecoline
/ chemistry
Carcinogenesis
/ genetics
Carcinoma, Squamous Cell
/ genetics
Cell Line, Tumor
DNA (Cytosine-5-)-Methyltransferases
/ metabolism
Gene Expression Regulation, Neoplastic
Gene Silencing
Humans
Metabolic Networks and Pathways
MicroRNAs
/ genetics
Mitochondrial Proteins
/ genetics
Mouth Neoplasms
/ genetics
Nitrosamines
/ chemistry
Retinal Dehydrogenase
/ genetics
Tretinoin
/ metabolism
DNA Methyltransferase 3B
DNA methylation
DNA methyltransferase (DNMT)
Epigenetic regulation
OSCC
Oral cancer
Retinoic acid (RA)
miR-30a
microRNA
Journal
Journal of biomedical science
ISSN: 1423-0127
Titre abrégé: J Biomed Sci
Pays: England
ID NLM: 9421567
Informations de publication
Date de publication:
02 Apr 2020
02 Apr 2020
Historique:
received:
13
01
2020
accepted:
26
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Epigenetic silencing of retinoic acid (RA) signaling-related genes have been linked with the pathogenesis and clinical outcome in oral squamous cell carcinoma (OSCC) carcinogenesis. However, the precise mechanisms underlying the abnormal silencing of RA signaling-related genes in OSCC have not been well investigated. Using combined analysis of genome-wide gene expression and methylation profile from 40 matched normal-tumor pairs of OSCC specimens, we found a set of retinoid signaling related genes are frequently hypermethylated and downregulated in OSCC patient samples, including alcohol dehydrogenase, iron containing 1 (ADHFE1) and aldehyde dehydrogenase 1 family, member A2 (ALDH1A2), which are the important rate-limiting enzymes in synthesis of RA. The expression of ADHFE1 and ALDH1A2 in OSCC patients was determine by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. The binding sites of miR-30a and miR-379 with DNA methyltransferase 3B (DNMT3B) were predicted using a series of bioinformatic tools, and validated using dual luciferase assay and Western blot analyses. The functions of miR-30a, miR-379, and DNMT3B were accessed by growth and colony formation analyses using gain- and loss-of-function approaches. Chromatin immunoprecipitation (ChIP) was performed to explore the molecular mechanisms by arecoline and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment. We demonstrated that deregulated miR-30a and miR-379 could represent a mechanism for the silencing of ADHFE1 and ALDH1A2 in OSCC through targeting DNMT3B. Ectopic expression of miR-30a and miR-379 could induce re-expression of methylation-silenced ADHFE1 and ALDH1A2, and lead to growth inhibition in oral cancer cells. Furthermore, the dysregulation of the miRNAs and DNMT-3B may result from exposure to tobacco smoking and betel quid chewing. Our results demonstrate that tobacco smoking and betel quid chewing could repress miR-30a and miR-379, which upregulate the DNMT3B expression, in turn, lead to the hypermethylation of ADHFE1 and ALDH1A genes, consequently, promote the oncogenic activity. These findings highlight the potential use of retinoids in combination with epigenetic modifiers for the prevention or treatment of oral cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Epigenetic silencing of retinoic acid (RA) signaling-related genes have been linked with the pathogenesis and clinical outcome in oral squamous cell carcinoma (OSCC) carcinogenesis. However, the precise mechanisms underlying the abnormal silencing of RA signaling-related genes in OSCC have not been well investigated.
METHODS
METHODS
Using combined analysis of genome-wide gene expression and methylation profile from 40 matched normal-tumor pairs of OSCC specimens, we found a set of retinoid signaling related genes are frequently hypermethylated and downregulated in OSCC patient samples, including alcohol dehydrogenase, iron containing 1 (ADHFE1) and aldehyde dehydrogenase 1 family, member A2 (ALDH1A2), which are the important rate-limiting enzymes in synthesis of RA. The expression of ADHFE1 and ALDH1A2 in OSCC patients was determine by quantitative real-time PCR (qRT-PCR) and immunohistochemistry. The binding sites of miR-30a and miR-379 with DNA methyltransferase 3B (DNMT3B) were predicted using a series of bioinformatic tools, and validated using dual luciferase assay and Western blot analyses. The functions of miR-30a, miR-379, and DNMT3B were accessed by growth and colony formation analyses using gain- and loss-of-function approaches. Chromatin immunoprecipitation (ChIP) was performed to explore the molecular mechanisms by arecoline and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) treatment.
RESULTS
RESULTS
We demonstrated that deregulated miR-30a and miR-379 could represent a mechanism for the silencing of ADHFE1 and ALDH1A2 in OSCC through targeting DNMT3B. Ectopic expression of miR-30a and miR-379 could induce re-expression of methylation-silenced ADHFE1 and ALDH1A2, and lead to growth inhibition in oral cancer cells. Furthermore, the dysregulation of the miRNAs and DNMT-3B may result from exposure to tobacco smoking and betel quid chewing.
CONCLUSIONS
CONCLUSIONS
Our results demonstrate that tobacco smoking and betel quid chewing could repress miR-30a and miR-379, which upregulate the DNMT3B expression, in turn, lead to the hypermethylation of ADHFE1 and ALDH1A genes, consequently, promote the oncogenic activity. These findings highlight the potential use of retinoids in combination with epigenetic modifiers for the prevention or treatment of oral cancer.
Identifiants
pubmed: 32238162
doi: 10.1186/s12929-020-00644-z
pii: 10.1186/s12929-020-00644-z
pmc: PMC7114797
doi:
Substances chimiques
MIRN30b microRNA, human
0
MIRN379 microRNA, human
0
MicroRNAs
0
Mitochondrial Proteins
0
Nitrosamines
0
Arecoline
4ALN5933BH
Tretinoin
5688UTC01R
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone
7S395EDO61
Alcohol Oxidoreductases
EC 1.1.-
hydroxyacid-oxoacid transhydrogenase
EC 1.1.99.24
Aldehyde Dehydrogenase 1 Family
EC 1.2.1
ALDH1A2 protein, human
EC 1.2.1.36
Retinal Dehydrogenase
EC 1.2.1.36
DNA (Cytosine-5-)-Methyltransferases
EC 2.1.1.37
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
46Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 101-2325-B-400-007
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 102-2325-B-400-007
Organisme : Ministry of Health and Welfare
ID : MOHW 108-TDU-B-212-144013
Organisme : National Health Research Institutes
ID : NHRI-CA102-PP02
Organisme : National Health Research Institutes
ID : NHRI-CA-103-PP02
Références
Mol Cancer. 2014 Jan 10;13:6
pubmed: 24410957
Cancer Res. 2005 Sep 15;65(18):8118-24
pubmed: 16166285
J Exp Clin Cancer Res. 2019 Jun 28;38(1):281
pubmed: 31253192
Annu Rev Pathol. 2011;6:345-64
pubmed: 21073338
Oral Oncol. 2001 Sep;37(6):477-92
pubmed: 11435174
Mol Oncol. 2016 Jun;10(6):895-909
pubmed: 27038552
Cancer Res. 2014 Dec 15;74(24):7560-72
pubmed: 25351956
J Clin Invest. 2013 Jun;123(6):2488-501
pubmed: 23635773
Mol Cell Biol. 2005 Dec;25(23):10591-603
pubmed: 16287870
J Pathol. 2013 Jul;230(3):298-309
pubmed: 23362108
J Biol Chem. 1997 Jul 25;272(30):18538-41
pubmed: 9228017
Br J Cancer. 2000 Jun;82(11):1871-4
pubmed: 10839305
Cancer Res. 2002 May 1;62(9):2455-61
pubmed: 11980632
Cell Growth Differ. 1995 Sep;6(9):1077-88
pubmed: 8519684
Mol Cancer. 2015 Dec 03;14:204
pubmed: 26634247
Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G195-202
pubmed: 16825659
Differentiation. 2007 Nov;75(9):853-70
pubmed: 17634071
J Cell Physiol. 2000 Nov;185(2):302-9
pubmed: 11025452
Int J Cancer. 1992 Dec 2;52(6):896-902
pubmed: 1459732
J Biol Chem. 1999 Sep 17;274(38):26783-8
pubmed: 10480883
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
J Oral Pathol Med. 2010 Sep;39(8):645-50
pubmed: 20412404
Invest New Drugs. 2011 Dec;29(6):1482-7
pubmed: 20596747
PLoS Genet. 2010 Jul 29;6(7):e1001043
pubmed: 20686660
Oral Oncol. 2010 Jun;46(6):414-7
pubmed: 20400366
Environ Health Perspect. 2014 Feb;122(2):131-7
pubmed: 24273234
Clin Epigenetics. 2018 Oct 20;10(1):126
pubmed: 30342560
Cancer Res. 2001 Oct 1;61(19):7065-70
pubmed: 11585737
Cell. 2007 Feb 23;128(4):683-92
pubmed: 17320506
Epidemiology. 2013 Sep;24(5):712-6
pubmed: 23867811
N Engl J Med. 1997 Oct 9;337(15):1021-8
pubmed: 9321529
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10
pubmed: 17890317
Genome Res. 2010 Apr;20(4):434-9
pubmed: 20219945
Onco Targets Ther. 2019 Oct 04;12:8105-8115
pubmed: 31632063
N Engl J Med. 2003 Nov 20;349(21):2042-54
pubmed: 14627790
J Surg Res. 2007 Mar;138(1):71-8
pubmed: 17187826
J Oral Maxillofac Pathol. 2017 May-Aug;21(2):252-259
pubmed: 28932035
J Clin Oncol. 2001 May 1;19(9):2456-71
pubmed: 11331325
BMC Cancer. 2013 Mar 22;13:142
pubmed: 23517143
J Nutr. 1998 Feb;128(2 Suppl):459S-462S
pubmed: 9478048
J Oncol. 2018 Aug 6;2018:5167829
pubmed: 30158978
Int J Oncol. 2017 Sep;51(3):867-876
pubmed: 28713929
Am J Hum Genet. 2011 Apr 8;88(4):450-7
pubmed: 21457905
Clin Cancer Res. 2013 Apr 1;19(7):1651-9
pubmed: 23322901
Mol Cell Oncol. 2014 Oct 29;1(2):e954827
pubmed: 27308324
RNA. 2008 May;14(5):872-7
pubmed: 18367714
J Oral Pathol Med. 1995 Nov;24(10):450-3
pubmed: 8600280
Mol Cell Biol. 1995 Jul;15(7):3945-59
pubmed: 7791800